Cancer supportive care is associated with care given to the patients suffering from various types of cancer. Supportive care is intended for relieving suffering of the patients and improving their quality of life. These treatments are not intended to cure the disease itself, however, to treat the side effects and symptoms such as pain and stress. The main aim of supportive care is to improve the quality of life of the patient. Cancer supportive care has become an important part of cancer treatment since the recent past.

Government organizations and institutions are focusing on promoting better palliative/supportive care to improve patients’ quality of life. For instance, the American Cancer Society has collaborated with various institutions such as National Palliative Care Research Center (NPCRC) (in 2007) to improve cancer supportive care and to promote palliative care. Moreover, the American Cancer Society Cancer Action Network (ACS CAN) is working to improve access to palliative care services for adults and children that are severely suffering from various types of cancer.  

Commercially available cancer supportive care drugs include, Granocyte, Neupogen, Zarzio, Pegfilgrastim, Longquex, Aranesp, Epogen, and other categories such as antiemetic’s, NSAID’s, and opioids.      

Cancer Supportive Care Drugs Market Drivers

High prevalence of various types of cancer is a key factor supporting growth of the global cancer supportive care drugs market. Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its invasive nature and prolonged duration of disease. According to National Cancer Institute, around 1,735,350 new cancer cases are expected to be diagnosed in the U.S. in 2018. The most common cancers are lung cancer, breast cancer, prostate cancer, melanoma, bladder cancer, and others.

Cancer treatment includes chemotherapy, radiation therapy, targeted therapy, hormone replacement therapy, and others. These therapies have their own advantages and side effects. Cancer supportive care drugs are primarily used to aid in treatment of side effects associated with various cancer treatments. Increasing demand for various cancer therapies, owing to high prevalence of the disease is expected to boost the global cancer supportive care drugs market growth over the forecast period. According to American Cancer Society, in 2017, around 222,500 new cases of lung cancer were registered and around 155,870 deaths recorded due to lung cancer in the U.S.

Moreover, drugs such as erythropoietin stimulating agents are on the World Health Organizations’ (WHO) essential medicine list, indicated for the treatment of anemia due to chemotherapy and other treatments. Effectiveness of biopharmaceutical drugs such as erythropoietin stimulating agents and g-colony stimulating factors in the treatment of cancer induced side effects (anemia) is expected to propel the global cancer supportive care drugs market growth over the forecast period.

However, biosimilar launches (as biosimilars are cheaper) in categories such as erythropoietin stimulating agents and g-colony stimulating factors is expected to restrain the global cancer supportive care drugs market growth over the forecast period. For instance, the U.S. Food & Drug Administration (FDA) recommended approval of Hospira’s Epogen biosimilar in 2017. Sandoz launched Zarxio (Filgrastim-sndz), a biosimilar of Filgrastim in 2015.   

Cancer Supportive Care Drugs Market Regional Insights

North America and Europe are expected to witness significant growth in the cancer supportive care drugs market over the forecast period. New product launches of cancer supportive care drugs and increasing demand for such drugs, owing to high prevalence of the disease is expected to facilitate growth of the cancer supportive care drugs market, in the U.S. For instance, according to the American Cancer Society, in 2017, around 225,000 cases of lung cancer were registered in the U.S. Furthermore, presence of leading manufacturers such as Amgen, Inc. in North America that are focused on research and development of new cancer supportive care drugs is a key factor promoting growth of the market in the region over the forecast period.

Moreover, competition to global manufacturers from generic manufacturers in India and China is expected to negatively impact growth of the global cancer supportive care drugs market over the forecast period.

Cancer Supportive Care Drugs Market Key Player

Key players operating in the cancer supportive care drugs market include Johnson & Johnson, Novartis AG, F.Hoffmann La-Roche Ltd., Amgen, Inc., Baxter International, Inc., Teva Pharmaceutical Industries Ltd., Acacia Pharma Ltd., Merck & Co., Inc., Helsinn Healthcare SA, and Heron Therapeutics.

Cancer Supportive Care Drugs Market Taxonomy

The global cancer supportive care drugs market is segmented on the basis of drug type, cancer type, distribution channel, and region.

By Drug Type -

  • Antiemetic
  • Bisphosphonates
  • Opioids
  • NSAIDs
  • G-Colony Stimulating Factors
  • Erythropoietin Stimulating Agents
  • Others

By Cancer Type -

  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Melanoma
  • Bladder Cancer
  • Leukemia
  • Ovarian Cancer
  • Others

By Distribution Channel -

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region -

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
N/A